Parse Biosciences Launches CRISPR Detect
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"We are thrilled to provide CRISPR Detect to the single cell community," states Charlie Roco, PhD, Chief Technology Officer of Parse Biosciences. "We are particularly excited about the responses from our early access customers around enabling genome scale screens and the potential to expand the usage of single cell CRISPR screening in drug discovery."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SEATTLE -- Businesswire -- Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, announced today the launch of CRISPR Detect, enabling single cell pooled CRISPR screens at unprecedented scale.
Bulk pooled CRISPR screening has been a valuable tool to understand gene function on a genome scale. Adding single cell resolution to pooled CRISPR screens pairs individual gene perturbations with rich whole transcriptome expression phenotypes. This approach has expanded the capabilities of pooled CRISPR screening to understand cell types of perturbed cells and quantify changes in gene expression, regulatory networks, signaling pathways, and other complex signatures. However, the applications and scale of these studies have been limited by the throughput and cost of droplet-based single cell RNA-seq technology.
CRISPR Detect brings the scale of existing Parse Evercode technology to single cell CRISPR screening by enabling users to pair perturbations and transcriptional profiles in up to one million cells in a single experiment. This scale will expand the applications of single cell CRISPR screening particularly in drug discovery where cost has limited their use to targeted validation studies.
“We are thrilled to provide CRISPR Detect to the single cell community,” states Charlie Roco, PhD, Chief Technology Officer of Parse Biosciences. “We are particularly excited about the responses from our early access customers around enabling genome scale screens and the potential to expand the usage of single cell CRISPR screening in drug discovery.”
Parse is also announcing the broad availability of UDIs (unique dual indexes) for all Evercode products. UDIs improve sequencing data quality and enable more Evercode sequencing libraries to be analyzed together.
CRISPR Detect and UDIs will be highlighted in an upcoming webinar on June 15 at 9:00 AM PT. For more information, visit https://parse.bio/3IFc8CR.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
With technology developed at The University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $50 million in capital and is now used by nearly 1,000 customers across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Gene Capture, and a data analysis solution.
Parse Biosciences is based in Seattle’s vibrant South Lake Union district, where it recently opened a 34,000 square foot headquarters and state-of-the-art laboratory. To learn more, please visit https://www.parsebiosciences.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005007/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Parse Biosciences
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 삼성전자, 케이뱅크와 손잡고 ‘세상 편한 AI 라이프 챌린지박스’ 선보여 - 뉴스와이어
- 투썸플레이스, 비비와 함께한 ‘아박’ 광고 조회수 1000만 뷰 돌파 - 뉴스와이어
- 아로마티카, 국내 뷰티 브랜드 최초 SBTi 승인 획득 - 뉴스와이어
- 압타머사이언스, 혈액 기반 폐암진단키트 인도시장 진출 위한 MOU 체결 - 뉴스와이어
- 동구바이오제약, 세계 최초 조루 복합제 ‘구세정’ 출시 예정 - 뉴스와이어
- LIG넥스원, 합동군사대와 ‘미래 국방 군사전문가 육성 MOU’ 체결 - 뉴스와이어
- LS일렉트릭-유니슨, 국산 풍력발전 기술경쟁력 강화 맞손 - 뉴스와이어
- 예술시장 진입을 위한 역량 강화 프로그램 ‘2024 청년예술가 역량강화 교육 기·성악 부문’ 참
- RWS 코리아, 최첨단 AI 탑재 번역툴 ‘트라도스 스튜디오 2024’ 출시 - 뉴스와이어
- 롯데건설, 안양 종합운동장 북측 재개발정비사업 수주 - 뉴스와이어